Global_Deals_BiosciBD.xls
 Share
The version of the browser you are using is no longer supported. Please upgrade to a supported browser.Dismiss

 
View only
 
 
ABCDEFGHIJKLMNOPQRSTUVWXYZAAABACADAEAFAGAHAI
1
Deal DateR&DClientDeal Size ($M)StageHas TagsDeal SourceDeal TypesDeal SubjectExclusivity
Upfront Cash ($M)
Upfront Equity ($M)
Contingent Equity ($M)
R&D Support ($M)
FTE Rate ($M)Loan ($M)
Dev / Reg Milestones ($M)
Other Milestones ($M)
Total Precommercial Payments ($M)
Sales Milestones ($M)
Deal Size ($M)EFR$200M (%)EFR$500M (%)EFR$1B (%)
Maximum Royalty (%)
Marketing Fee (%)
Transfer Price (%)
Manufacture Cost + (%)
Profit Split (%)Company CategoryDiseaseIndicationTechnologySub-TechnologyTerritory
2
10/2016AstraZenecaInsmed 150.00 Phase IPRDevelopment, License, OptionAZD7986 DPP1 inhibitor for non-CF bronchiectasisExclusive 30.00 150.00 Top PharmaRespiratoryOther RespiratorySyntheticsSmall MoleculeWorldwide
3
10/2016AstraZeneca, MedImmuneAllergan 1,520.00 Phase IIPRDevelopment, LicenseMEDI2070 IL-23 monoclonal antibody for Crohn's and ulcerative colitisExclusive 250.00 1,520.00 Top Pharma, Mid Tier PharmaGastrointestinal
IBD - Crohn's Disease, IBD - Ulcerative Colitis
MonoclonalsHuman AbsWorldwide
4
10/2016Crescendo BiologicsTakeda, Millennium 790.00 DiscoveryPRDevelopment, Equity, License, ResearchHumabody-based therapeutics for cancer indications 790.00 790.00 Top PharmaCancerBroad Focus CancerMonoclonals, TransgenicsFragmentsWorldwide
5
10/2016Ocular TherapeutixRegeneron Pharmaceuticals 315.00 Preclinical, FormulationPRDevelopment, License, OptionSustained release formulation of Aflibercept for wet AMDExclusive 10.00 255.00 265.00 50.00 315.00 Major Biotech, 2013-15 IPOsOphthalmicAge-Related Macular DegenerationDrug Delivery, Recombinant DNASustained ReleaseWorldwide
6
9/2016Arrowhead PharmaceuticalsAmgen 673.50 PreclinicalPRDevelopment, Equity, License, OptionRNAi ARC-LPA program and option to additional undisclosed RNAi product for cardiovascular diseasesExclusive 35.00 21.50 673.50 673.50 Major BiotechCardiovascularAtherosclerosis/Coronary Artery DiseaseOligonucleotidesRNAiWorldwide
7
9/2016BioNTechRoche, Genentech 310.00 DiscoveryPR
Co-Development, Co-Promotion, License, Option, Supply
IVAC Mutanome mRNA vaccine platform for cancerExclusive 310.00 310.00 Top PharmaCancerBroad Focus CancerVaccinesWorldwide
8
9/2016Evotec AGBayer 350.20 DiscoveryPRDevelopment, License, ResearchMulti-target collaboration to develop clinical candidates for kidney diseasesExclusive 15.60 350.20 350.20 Top PharmaRenalBroad Focus RenalWorldwide
9
9/2016LigandSeelos Therapeutics 149.80 Phase IIPRDevelopment, License, Loan, SupplyPortfolio of four products including SLS-006 for CNS and respiratory indications 1.30 3.50 149.80 149.80 10.00 Central Nervous System, Respiratory
Broad Focus Central Nervous System, Broad Focus Respiratory, Pain, Parkinson's Disease, Sleep Disorders
SyntheticsSmall MoleculeWorldwide
10
9/2016Madrigal PharmaceuticalsTarveda Therapeutics 249.00 PreclinicalPRDevelopment, License, ResearchHSP90 Drug Conjugate program including PEN-866 for cancerExclusive 249.00 CancerBroad Focus CancerSyntheticsSmall MoleculeWorldwide
11
9/2016Medigenebluebird bio 1,000.00 DiscoveryPRDevelopment, License, ResearchT-cell receptor immunotherapy products for up to four cancer targetsExclusive 15.00 1,000.00 1,000.00 2013-15 IPOsCancerBroad Focus CancerCell Therapy - Stem Cells/FactorsWorldwide
12
9/2016OncoImmunePfizer 250.00 PreclinicalPRDevelopment, License, OptionAnti-CTLA4 mAbs including ONC-392 for immuno-oncology indicationsExclusive 250.00 250.00 Top PharmaCancerBroad Focus CancerMonoclonalsWorldwide
13
8/2016AdvaxisAmgen 540.00 PreclinicalSEC FilingDevelopment, Equity, LicenseADXS-NEO personalized immunotherapy for cancerExclusive 40.00 25.00 540.00 540.00 Major BiotechCancerBroad Focus CancerVaccinesWorldwide
14
8/2016GenmabGilead 282.00 DiscoveryPRDevelopment, License, Option, ResearchDuoBody technology to develop bispecific antibody products for HIVExclusive 5.00 282.00 Major BiotechInfectious-ViralHuman Immunodeficiency Virus/HIVMonoclonalsBispecificWorldwide
15
8/2016MEI PharmaHelsinn 469.00 Phase IIPRDevelopment, Equity, LicensePracinostat HDAC inhibitor for leukemiaExclusive 15.00 5.00 5.00 469.00 CancerLeukemiaSyntheticsSmall MoleculeWorldwide
16
7/2016AstraZenecaLEO Pharma 1,115.00 Phase IIPRDevelopment, License, SupplyTralokinumab anti-IL-13 mAb for dermatologic indications including atopic dermatitisExclusive 115.00 115.00 1,000.00 1,115.00 Top PharmaDermatologicBroad Focus Dermatologic, DermatitisMonoclonalsHuman AbsWorldwide
17
7/2016Johnson & Johnson, JanssenGlaxoSmithKline 230.00 Phase IPRDevelopment, LicenseCNTO 7160 anti-IL-33R mAbExclusive 230.00 Top PharmaUnlimitedMonoclonalsWorldwide
18
7/2016Moderna TherapeuticsVertex 315.00 Discovery, Orphan IndicationPR
Development, Equity, License, Loan, Research
messenger Ribonucleic Acid therapeutics for cystic fibrosisExclusive 20.00 20.00 275.00 315.00 315.00 Major BiotechRespiratoryCystic FibrosisOligonucleotides, Transcription FactorsRNAiWorldwide
19
7/2016PfenexJazz Pharmaceuticals 181.00 PreclinicalPRDevelopment, License, OptionUndisclosed hematology product candidates including option to recombinant pegaspargase productExclusive 15.00 41.00 56.00 125.00 181.00 2013-15 IPOsHematologicRecombinant DNAWorldwide
20
7/2016Sorrento TherapeuticsServier 970.90 PreclinicalYesSEC FilingLicenseSTI-A1110 (human anti-PD-1 immune checkpoint mAb) for immuno-oncologyExclusive 27.40 85.50 80.00 192.90 778.00 970.90 Mid Tier PharmaCancerLeukemia, Solid TumorsMonoclonalsHuman AbsWorldwide
21
7/2016Sprint BiosciencePetra Pharma 243.00 Lead MoleculePRDevelopment, License, ResearchPIP4k2a inhibitor program targeting tumor metabolism 3.00 243.00 243.00 CancerBroad Focus CancerWorldwide
22
7/2016UCBSyndax Pharmaceuticals 374.50 PreclinicalPRDevelopment, LicenseUCB6352 anti-CSF-1R mAb for cancerExclusive 374.50 Mid Tier PharmaCancerBroad Focus CancerMonoclonalsWorldwide
23
7/2016X-ChemBayer 528.00 DiscoveryPRLicense, Option, ResearchDNA-encoded X-Chem library and screening platform for undislcosed indicationsExclusive 528.00 528.00 Top PharmaScreening, SyntheticsSmall MoleculeWorldwide
24
6/2016Eleven BiotherapeuticsRoche 270.00 PreclinicalYesSEC FilingLicense, OptionEBI-031 (IL-6 antagonist antibody) for diabetic macular edema and uveitisExclusive 7.50 197.50 65.00 270.00 270.00 7.50 7.50 7.50 15.00 Top Pharma, 2013-15 IPOsOphthalmicBroad Focus OphthalmicMonoclonalsHumanized AbsWorldwide
25
6/2016Innovative Targeting SolutionsMerck 150.00 DiscoveryPRLicenseHuTARG platform to identify antibodies undisclosed targetsExclusive 150.00 Top PharmaMonoclonalsHuman AbsWorldwide
26
6/2016TakedaUltragenyx Pharmaceutical 232.50 Preclinical, Orphan IndicationYesSEC Filing
Co-Development, Co-Promotion, Equity, License, Option, Research
Undisclosed compound for rare genetic diseasesExclusive 40.00 35.00 82.50 82.50 150.00 232.50 Top Pharma, 2013-15 IPOsOther/MiscellaneousGenetic DisordersSyntheticsSmall MoleculeWorldwide
27
6/2016Theravance BiopharmaTakeda, Millennium 125.00 Phase IIYesSEC FilingCo-Promotion, Development, LicenseTD-8954 (serotonin receptor agonist) for gastrointestinal motility disordersExclusive 15.00 110.00 125.00 125.00 Top PharmaGastrointestinalOther GastrointestinalSyntheticsSmall MoleculeWorldwide
28
5/2016Agios PharmaceuticalsCelgene 1,002.00 DiscoveryYesSEC Filing
Co-Development, Co-Promotion, License, Option, Research
Immuno-oncology targets for metabolic diseases, plus inflammation & autoimmuneExclusive 200.00 209.00 468.00 877.00 125.00 1,002.00 50.00 Major Biotech, 2013-15 IPOs
Autoimmune/Inflammatory, Cancer, Endocrinological & Metabolic
Broad Focus Autoimmune/Inflammatory, Broad Focus Cancer, Broad Focus Endocrinological & Metabolic
SyntheticsSmall MoleculeWorldwide
29
5/2016Fortress Biotech, Checkpoint TherapeuticsTG Therapeutics 178.00 Preclinical, Orphan IndicationYesSEC FilingCo-Development, SublicenseJBET070 & JBET050 (BRD4 inhibitors) for hematological malignanciesExclusive 1.00 178.00 178.00 CancerLeukemia, Lymphoma, Multiple MyelomaSyntheticsSmall MoleculeWorldwide
30
5/2016Immune PharmaceuticalsNovel Pain Therapeutics 161.00 Phase II, FormulationYesSEC FilingDevelopment, Equity, License, OptionAmiKet and AmiKet Nano for peripheral neuropathic painExclusive 15.00 1.00 25.00 41.00 120.00 161.00 7.50 8.75 9.38 10.00 Central Nervous SystemPainDrug Delivery, SyntheticsSmall Molecule, TopicalWorldwide
31
5/2016InventivaBoehringer Ingelheim 189.30 DiscoveryPRDevelopment, License, ResearchIdiopathic pulmonary fibrosis drug discoveryExclusive 189.30 189.30 Mid Tier PharmaRespiratoryOther RespiratoryWorldwide
32
5/2016MacroGenicsJohnson & Johnson, Janssen 740.00 PreclinicalPR
Co-Development, Co-Promotion, License, Option
MGD015 (anti-CD3 bispecific DART molecule) for hematological cancer and solid tumorsExclusive 75.00 365.00 440.00 300.00 740.00 Top Pharma, 2013-15 IPOsCancerBroad Focus CancerMonoclonalsBispecificWorldwide
33
5/2016Wave Life SciencesPfizer 911.00 DiscoveryYesSEC FilingEquity, License, Option, ResearchAntisense and RNAi technology for up to 5 genetically targeted therapies for metabolic diseasesExclusive 10.00 30.00 911.00 911.00 Top Pharma, 2013-15 IPOsEndocrinological & MetabolicBroad Focus Endocrinological & MetabolicOligonucleotidesAntisense/Triple helix, RNAiWorldwide
34
4/2016arGEN-XAbbVie 685.00 PreclinicalPR
Co-Development, Co-Promotion, License, Option
ARGX-115 human antibody targeting GARP for immuno-oncology indicationsExclusive 40.00 685.00 685.00 Top PharmaCancerBroad Focus CancerMonoclonalsHuman AbsWorldwide
35
4/2016Bristol-Myers SquibbEiger BioPharmaceuticals 194.00 Phase II, FormulationYesSEC FilingEquity, LicensePegalated Interferon Lambda-1a to treat hepatitis delta virusExclusive 2.00 3.00 61.00 66.00 128.00 194.00 Top PharmaInfectious-ViralOther Infectious-ViralDrug Delivery, Recombinant DNAPEG ProductsWorldwide
36
4/2016CytomX TherapeuticsAbbVie 490.00 PreclinicalYesSEC Filing
Co-Development, Co-Promotion, License, Option, Research
Probody-drug conjugates against CD71 for solid and hematologic cancersExclusive 20.00 490.00 490.00 35.00 Top Pharma, 2013-15 IPOsCancer
Leukemia, Lymphoma, Multiple Myeloma, Solid Tumors
MonoclonalsConjugatesWorldwide
37
4/2016CytomX TherapeuticsAbbVie 285.00 DiscoveryYesSEC FilingLicense, ResearchProbody-drug conjugates against two oncology targetsExclusive 10.00 285.00 285.00 Top Pharma, 2013-15 IPOsCancerBroad Focus CancerMonoclonalsConjugatesWorldwide
38
4/2016Enumeral BiomedicalPieris Pharmaceuticals 211.50 PreclinicalYesSEC FilingLicense, OptionENUM 388D4 (anti-PD-1 antibody) to develop Anticalin fusion proteins for cancerExclusive 1.00 37.75 37.75 76.50 135.00 211.50 CancerBroad Focus CancerMonoclonalsBispecificWorldwide
39
4/2016Intellia TherapeuticsRegeneron Pharmaceuticals 445.00 Discovery, Orphan IndicationYesSEC Filing
Co-Development, Co-Promotion, Equity, License, Option, Research
CRISPR/Cas gene editing technology for transthyretin amyloidosis plus up to 9 other targetsExclusive 75.00 50.00 135.00 260.00 185.00 445.00 Major Biotech
Liver & Gallbladder Diseases, Other/Miscellaneous
Genetic Disorders, Other Liver & Gallbladder Diseases
OligonucleotidesGene TherapyWorldwide
40
4/2016Progenics PharmaceuticalsBayer 183.00 PreclinicalYesSEC FilingLicensePSMA antibody technology combined with targeted thorium conjugate technology for prostate cancerExclusive 4.00 49.00 53.00 130.00 183.00 Top PharmaCancerProstateMonoclonalsConjugates, Human AbsWorldwide
41
4/2016Sosei, Heptares TherapeuticsAllergan 3,340.00 Phase IPRDevelopment, LicenseSmall molecule agonists targeting muscarinic M1 and M4 receptors for CNS disordersExclusive 125.00 50.00 665.00 840.00 2,500.00 3,340.00 Mid Tier PharmaCentral Nervous System
Alzheimer's Disease, Broad Focus Central Nervous System
SyntheticsSmall MoleculeWorldwide
42
4/2016ZymeworksGlaxoSmithKline 908.00 DiscoveryPRDevelopment, License, Option, ResearchBi-specific antibodies derived from Azymetric drug discovery platform for undisclosed indicationsExclusive 36.00 152.00 188.00 720.00 908.00 Top PharmaMonoclonalsBispecificWorldwide
43
3/2016Blueprint MedicinesRoche 1,010.00 DiscoveryYesSEC FilingCo-Development, License, Option, ResearchFive small molecule programs targeting kinases for cancer immunotherapyExclusive 45.00 215.00 1,010.00 1,010.00 Top Pharma, 2013-15 IPOsCancerBroad Focus CancerSyntheticsSmall MoleculeWorldwide
44
3/2016Chiome BioscienceADC Therapeutics 99.00 PreclinicalPRLicense, OptionOption to LIV-2008b anti-TROP-2 antibody to be developed as an ADC for cancerExclusive 99.00 99.00 CancerBroad Focus CancerMonoclonalsConjugatesWorldwide
45
3/2016DiCE MoleculesSanofi 2,258.00 DiscoveryPRCo-Development, Equity, License, ResearchSmall molecule discovery for up to 12 undisclosed targets 2,258.00 2,258.00 Top PharmaSyntheticsSmall MoleculeWorldwide
46
3/2016IntrexonRelieve Genetics 56.80 DiscoveryPREquity, LicenseNon-opioid gene therapy using IL-10 for neuropathic painExclusive 4.30 56.80 56.80 2013-15 IPOsCentral Nervous SystemPainOligonucleotidesGene TherapyWorldwide
47
3/2016IntrexonExotech Bio 57.50 DiscoveryPREquity, LicenseEngineered cell lines to produce tumor-targeted allogeneic exosomes for cancerExclusive 4.30 56.80 57.50 2013-15 IPOsCancerBroad Focus CancerOligonucleotidesGene Therapy, RNAiWorldwide
48
2/2016Precision BioSciencesShire, Baxalta 1,705.00 DiscoveryPR
Co-Development, Co-Promotion, License, Option, Research
ARCUS genome editing technology to develop allogeneic CAR T cell therapeutics for cancerExclusive 105.00 1,705.00 1,705.00 Major BiotechCancerBroad Focus CancerCell Therapy - Stem Cells/FactorsWorldwide
49
2/2016Precision BioSciencesShire, Baxalta 1,705.00 DiscoveryPR
Co-Development, Co-Promotion, License, Option, Research
ARCUS genome editing technology to develop allogeneic CAR T cell therapeutics for cancerExclusive 890.00 890.00 1,705.00 Major BiotechCancerBroad Focus CancerCell Therapy - Stem Cells/FactorsWorldwide
50
1/2016Arena PharmaceuticalsBoehringer Ingelheim 262.00 DiscoveryPRLicense, ResearchDrug candidates targeting undisclosed orphan GPCR for CNS and psychiatric indicationsExclusive 262.00 262.00 Mid Tier PharmaCentral Nervous System, PsychiatricSchizophreniaWorldwide
51
1/2016C4 TherapeuticsRoche 750.00 DiscoveryPRDevelopment, License, Option, ResearchDegronimid small molecule technology to develop targeted protein degradation therapeuticsExclusive 750.00 750.00 Top PharmaSyntheticsSmall MoleculeWorldwide
52
1/2016
Cancer Research UK, Cancer Research Technology
Merck 515.00 Lead MoleculePRDevelopment, License, ResearchPRMT5 inhibitors for cancer and hematological disordersExclusive 15.00 515.00 515.00 Top Pharma, Research InstitutionCancer, Hematologic
Breast, Leukemia, Lung, Lymphoma, Melanoma, Other Hematologic, Sickle Cell Disease
Worldwide
53
1/2016
Catalent Pharma Solutions, Redwood Bioscience
Roche 619.00 DiscoveryPRLicense, Option, ResearchSMARTag precision protein-chemical engineering technology for undisclosed indiactionsNon-exclusive 1.00 619.00 Top Pharma, 2013-15 IPOsMonoclonalsConjugatesWorldwide
54
1/2016Complix NVMerck 280.00 DiscoveryPRDevelopment, License, Option, ResearchCell-Penetrating Alphabodies against up to two undisclosed intracellular cancer targetsExclusive 280.00 280.00 Top PharmaCancerBroad Focus CancerWorldwide
55
1/2016Innate PharmaSanofi 436.00 DiscoveryPRDevelopment, License, ResearchTwo bispecific cell engager programs targeting NKp46 for immuno-oncology indicationsExclusive 436.00 436.00 Top PharmaCancerBroad Focus CancerMonoclonalsBispecificWorldwide
56
1/2016Momenta PharmaceuticalsMylan 245.00 PreclinicalYesSEC Filing
Co-Development, Co-Promotion, License, Option
Six biosimilar products including Orencia (abatacept)Exclusive 45.00 245.00 245.00 50.00 Autoimmune/InflammatoryRheumatoid ArthritisGenerics, Recombinant DNAWorldwide
57
1/2016Quartet MedicineMerck 575.00 PreclinicalPRDevelopment, License, OptionSmall molecules targeting tetrahydrobiopterin pathway for chronic pain, option to acquire QuartetExclusive 10.00 10.00 575.00 575.00 Top PharmaCentral Nervous SystemPainSyntheticsSmall MoleculeWorldwide
58
1/2016SymphogenShire, Baxalta 1,775.00 PreclinicalPRDevelopment, License, OptionOption to six checkpoint therapies for undisclosed immuno-oncology indicationsExclusive 175.00 1,775.00 1,775.00 Major BiotechCancerBroad Focus CancerMonoclonalsWorldwide
59
1/2016Warp Drive BioSanofi 750.00 DiscoveryPR
Co-Promotion, Development, Equity, License, Option, Research
SMART and Genome Mining platforms to discover oncology therapeutics and antibioticsExclusive 750.00 750.00 Top PharmaCancer, Infectious-Bacterial
Broad Focus Cancer, Broad Focus Infectious-Bacterial
SyntheticsSmall MoleculeWorldwide
60
12/2015Bavarian NordicJohnson & Johnson, Janssen 171.00 Lead MoleculeYesSEC FilingCo-Development, License, OptionMVA-BN technology for use in vaccine for HPVExclusive 9.00 171.00 171.00 Top PharmaCancer, Infectious-ViralCervical, Other Infectious-ViralVaccinesWorldwide
61
12/2015BioAtlaPfizer 1,000.00 DiscoveryPRCross-License, Development, OptionConditionally Active Biologic antibodies combined with ADC payloads for cancerExclusive 1,000.00 1,000.00 Top PharmaCancerBroad Focus CancerMonoclonalsConjugatesWorldwide
62
12/2015BioAtlaPfizer 1,000.00 DiscoveryPRCross-License, Development, OptionConditionally Active Biologic antibodies combined with ADC payloads for cancerExclusive 1,000.00 Top PharmaCancerBroad Focus CancerMonoclonalsConjugatesWorldwide
63
12/2015CRISPR TherapeuticsBayer 390.00 Discovery, Orphan IndicationPRJoint VentureCasebia JV (Cas9 technology & protein engineering) for blood disorders, blindness & heart diseaseExclusive 20.00 35.00 35.00 300.00 390.00 390.00 50.00 Top Pharma
Cardiovascular, Hematologic, Ophthalmic, Other/Miscellaneous
Broad Focus Cardiovascular, Broad Focus Hematologic, Broad Focus Ophthalmic, Genetic Disorders
OligonucleotidesGene TherapyWorldwide
64
12/2015Galapagos NVGilead 2,080.00 Phase IIYesSEC Filing
Co-Development, Co-Promotion, Equity, License, Option
Filgotinib JAK1-selective inhibitor for inflammatory diseasesExclusive 300.00 425.00 755.00 1,480.00 600.00 2,080.00 50.00 Major Biotech, 2013-15 IPOsAutoimmune/Inflammatory, GastrointestinalIBD - Crohn's Disease, Rheumatoid ArthritisSyntheticsSmall MoleculeWorldwide
65
12/2015IntrexonFibrocell Science 87.50 PreclinicalYesSEC FilingLicenseFibroblast platform combined with cellular engineering to generate cell-based therapeuticsExclusive 10.00 30.00 25.00 65.00 22.50 87.50 2013-15 IPOsAutoimmune/InflammatoryOsteoarthritis, Scleroderma
Cell Therapy - Stem Cells/Factors, Oligonucleotides
Gene TherapyWorldwide
66
12/2015Pieris PharmaceuticalsRoche 415.70 DiscoveryYesSEC FilingDevelopment, License, ResearchAnticalin-based drug candidates against an undisclosed cancer-immunotherapy targetExclusive 6.40 297.70 118.00 415.70 Top PharmaCancerBroad Focus CancerRecombinant DNAWorldwide
67
12/2015SQZ BiotechRoche 500.00 DiscoveryPRDevelopment, License, ResearchCellSqueeze platform to develop engineered B cells for cancerExclusive 500.00 500.00 Top PharmaCancerBroad Focus CancerCell Therapy - Stem Cells/FactorsWorldwide
68
12/2015XomaNovo Nordisk 295.00 Phase IYesSEC FilingLicense, OptionXMetA program of allosteric monoclonal antibodies for diabetesExclusive 5.00 295.00 295.00 Top PharmaEndocrinological & MetabolicDiabetesMonoclonalsHuman AbsWorldwide
69
12/2015ZymeworksGlaxoSmithKline 440.00 DiscoveryPRDevelopment, License, ResearchEFECT platform to develop up to 4 Fc-engineered monoclonal and bi-specific antibody therapeuticsExclusive 440.00 440.00 Top PharmaMonoclonalsBispecificWorldwide
70
11/2015AblynxNovo Nordisk 400.00 DiscoveryPRDevelopment, License, Option, ResearchNanobody based therapeutics against undisclosed targetsExclusive 5.30 4.30 400.00 400.00 Top PharmaMonoclonalsFragmentsWorldwide
71
11/2015BioNTechSanofi 1,560.00 DiscoveryPR
Co-Development, Co-Promotion, License, Option, Research
Five synthetic messenger RNA immunotherapies for cancerExclusive 1,560.00 1,560.00 Top PharmaCancerBroad Focus CancerWorldwide
72
11/2015Fujifilm, Cellular Dynamics InternationalRoche 83.00 DiscoveryPRLicense, SupplyiPSC-derived iCell products for use in high throughput screening and lead optimizationExclusive 83.00 83.00
Top Pharma, Japanese Pharma, 2013-15 IPOs
Cell Therapy - Stem Cells/Factors, ScreeningWorldwide
73
11/2015Hanmi PharmaceuticalSanofi 4,245.00 Phase IIPR
Co-Promotion, Development, License, Option
Diabetes portfolio including efpeglenatide, weekly insulin and GLP-1-RA/insulin drug combinationExclusive 435.00 3,810.00 4,245.00 Top PharmaEndocrinological & MetabolicDiabetesPeptides, Recombinant DNAWorldwide
74
11/2015Idera PharmaceuticalsGlaxoSmithKline 100.50 DiscoveryPRDevelopment, License, ResearchThird generation antisense molecules for renal diseaseExclusive 2.50 98.00 100.50 100.50 5.00 Top PharmaRenalBroad Focus RenalOligonucleotidesAntisense/Triple helixWorldwide
75
11/2015InterproteinIpsen 177.00 DiscoveryPRDevelopment, License, Option, ResearchProtein-protein interaction and helix-loop-helix-peptide technologies for endocrinology indications 177.00 177.00 Mid Tier PharmaEndocrinological & MetabolicBroad Focus Endocrinological & MetabolicPeptidesWorldwide
76
11/2015Lexicon PharmaceuticalsSanofi 1,720.00 Phase IIIYesSEC Filing
Co-Development, Co-Promotion, License, Option
Sotagliflozin (LX4211 SGLT-1 and SGLT-2 dual inhibitor) for diabetesExclusive 300.00 430.00 730.00 990.00 1,720.00 40.00 Top PharmaEndocrinological & MetabolicDiabetesSyntheticsSmall MoleculeWorldwide
77
11/2015LillyIgnyta 64.30 Phase IYesSEC FilingDevelopment, Equity, LicenseTaladegib small molecule hedgehog/smoothened antagonist for cancerExclusive 2.00 24.30 64.30 64.30 Top Pharma, 2013-15 IPOsCancerBroad Focus CancerSyntheticsSmall MoleculeWorldwide
78
11/2015Sosei, Heptares TherapeuticsTeva 410.00 PreclinicalPRDevelopment, LicenseSmall molecule CGRP antagonists for migraineExclusive 10.00 410.00 410.00 Mid Tier PharmaCentral Nervous SystemMigraneSyntheticsSmall MoleculeWorldwide
79
11/2015Sosei, Heptares TherapeuticsPfizer 1,890.00 DiscoveryPRDevelopment, License, ResearchStaR proteins and structures against up to 10 GPCR targetsExclusive 33.00 1,890.00 1,890.00 Top PharmaWorldwide
80
10/2015Alpine Immune SciencesKite Pharma 535.90 DiscoveryYesSEC FilingLicense, ResearchTransmembrane immunomodulatory protein technology to engineer CAR and TCR cancer productsExclusive 5.00 0.90 535.90 535.90 2013-15 IPOsCancerBroad Focus CancerCell Therapy - Stem Cells/FactorsWorldwide
81
10/2015Arcturus TherapeuticsUltragenyx Pharmaceutical 322.00 Discovery, Orphan IndicationPRDevelopment, License, Option, ResearchUNA Oligomer chemistry and LUNAR nanoparticle delivery platform to develop RNA therapeuticsExclusive 10.00 322.00 322.00 2013-15 IPOsOther/MiscellaneousGenetic DisordersOligonucleotidesWorldwide
82
10/2015CRISPR TherapeuticsVertex 525.00 Discovery, Orphan IndicationYesSEC Filing
Co-Development, Equity, License, Loan, Option, Research
Up to six CRISPR-Cas9 gene editing-based productsExclusive 75.00 30.00 525.00 525.00 50.00 Major Biotech
Hematologic, Other/Miscellaneous, Respiratory
Cystic Fibrosis, Genetic Disorders, Sickle Cell Disease
OligonucleotidesGene TherapyWorldwide
83
10/2015Five PrimeBristol-Myers Squibb 1,737.50 Phase IYesSEC Filing
Co-Development, Co-Promotion, License, Option
CSF1R antibody program including FPA008 for immuno-oncology indicationsExclusive 350.00 1,737.50 1,737.50 Top Pharma, 2013-15 IPOsAutoimmune/Inflammatory, Cancer
Broad Focus Autoimmune/Inflammatory, Broad Focus Cancer
MonoclonalsHumanized AbsWorldwide
84
10/2015GlycotopeOctapharma 90.50 DiscoveryPRDevelopment, Equity, LicenseIP covering recombinant technology and acquisition of undisclosed minority equity stakeExclusive 90.50 90.50 HematologicRecombinant DNAWorldwide
85
10/2015Immunomic TherapeuticsAstellas Pharma 300.00 PreclinicalPRDevelopment, LicenseLAMP-vax DNA vaccine platform including ARA-LAMP-vax to prevent and treat allergic diseasesExclusive 300.00 300.00 10.00 Japanese PharmaAllergicFood/Pet AllergiesVaccinesWorldwide
86
10/2015Novera TherapeuticsJohnson & Johnson, Janssen 348.50 DiscoveryPRDevelopment, License, Option, ResearchSmall molecule drug candidates for haematological cancersExclusive 348.50 348.50 Top PharmaCancerLeukemia, LymphomaSyntheticsSmall MoleculeWorldwide
87
9/2015ChromocellAstellas Pharma 515.00 PreclinicalPR
Co-Development, Co-Promotion, License, Option
CC8464 peripherally restricted NaV1.7 antagonist and back up compounds for pain 15.00 515.00 515.00 Japanese PharmaCentral Nervous SystemPainSyntheticsSmall MoleculeWorldwide
88
9/2015City of HopeSorrento Therapeutics, LA Cell 170.00 DiscoveryYesSEC FilingEquity, License, ResearchModified monoclonal antibody immunotherapies for cancerExclusive 2.00 170.00 170.00 Research InstitutionCancerBroad Focus CancerMonoclonalsWorldwide
89
9/2015GenciaTakeda 500.00 DiscoveryPRDevelopment, License, ResearchMAGR agonists for inflammation and oncology indicationsExclusive 500.00 500.00 Top PharmaAutoimmune/Inflammatory, CancerSyntheticsSmall MoleculeWorldwide
90
9/2015NurixCelgene 572.00 DiscoveryPR
Co-Development, Co-Promotion, Equity, License, Option, Research
Small molecule activators and inhibitors of E3 ubiquitin ligases and E2 conjugating enzymesExclusive 150.00 17.00 572.00 572.00 50.00 Major BiotechAutoimmune/Inflammatory, Cancer
Broad Focus Autoimmune/Inflammatory, Broad Focus Cancer
SyntheticsSmall MoleculeWorldwide
91
9/2015Senhwa BiosciencesChaperone Therapeutics 102.70 PreclinicalPRDevelopment, Equity, LicenseUndisclosed small molecules for proteopathiesExclusive 102.70 Central Nervous SystemSyntheticsSmall MoleculeWorldwide
92
9/2015VM PharmaPurdue Pharma 213.00 Phase IPRDevelopment, LicenseVM-902A allosteric selective tropomyosin receptor kinase A inhibitor and back up compounds for painExclusive 213.00 Mid Tier PharmaCentral Nervous SystemPainSyntheticsSmall MoleculeWorldwide
93
9/2015XencorAmgen 1,702.50 Preclinical, DiscoveryYesSEC FilingDevelopment, License, ResearchXmAb bispecific antibodies for six programs including anti-CD38 bispecific T cell engagerExclusive 45.00 125.00 452.50 622.50 1,080.00 1,702.50 Major Biotech, 2013-15 IPOsCancerBroad Focus Cancer, Multiple MyelomaMonoclonalsBispecificWorldwide
94
9/2015XomaNovartis 530.50 PreclinicalYesSEC FilingLicense, LoanXOMA 089 (Anti-TGF-beta antibody) for immuno-oncology indicationsExclusive 37.00 13.50 530.50 530.50 Top PharmaCancerBroad Focus CancerMonoclonalsHuman AbsWorldwide
95
8/2015Alligator BioscienceJohnson & Johnson, Janssen 700.00 Phase IPRDevelopment, Equity, LicenseADC-1013 fully human anti-CD40 antibody for cancerExclusive 700.00 700.00 Top PharmaCancerBroad Focus CancerMonoclonalsHuman AbsWorldwide
96
8/2015Apeiron Biologics, Evotec AGSanofi 219.00 PreclinicalPRDevelopment, LicenseSmall molecule-based cancer immunotherapiesExclusive 219.00 Top PharmaCancerSyntheticsSmall MoleculeWorldwide
97
8/2015AVEO Pharmaceuticals, Aveo OncologyNovartis 326.45 PreclinicalYesSEC FilingDevelopment, LicenseAV-380 (anti-GDF15 antibody) for cachexiaExclusive 18.45 158.00 176.45 150.00 326.45 Top PharmaCardiovascular, Renal, Respiratory
Chronic Obstructive Pulmonary Disease, Congestive Heart Failure, Other Renal
MonoclonalsHumanized AbsWorldwide
98
8/2015Cytos BiotechnologyCheckmate Pharmaceuticals 90.00 Phase IPRLicenseCYT003 (Toll-like receptor 9 VLP platform) for oncology applicationsExclusive 90.00 CancerBroad Focus CancerOligonucleotides, VaccinesWorldwide
99
8/2015Evotec AGSanofi 332.00 DiscoveryPRDevelopment, License, ResearchBeta cell replacement therapy for diabetesExclusive 3.30 332.00 332.00 Top PharmaEndocrinological & Metabolic
Broad Focus Endocrinological & Metabolic, Diabetes
Cell Therapy - Stem Cells/FactorsWorldwide
100
8/2015GenmabNovo Nordisk 502.00 DiscoveryPRDevelopment, License, ResearchDuoBody technology to develop bispecific antibodies against two undisclosed targets excluding cancerExclusive 2.00 502.00 502.00 Top PharmaMonoclonalsBispecificWorldwide
Loading...
Main menu